PARI GmbH
The PARI Group is based in Bavaria, southern Germany. There are also international branch offices and a worldwide distribution network. All our employees, along with our management team (which has been stable for years), can look back on the company™s history of more than 100 years in business.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
From a small-scale manufacturer, to a company with an international reputation for excellence.
PARI was founded in Wuppertal in 1906 and has progressed from a small manufacturer to a globally respected specialist in respiratory therapy. At present, the PARI business group has headquarters in Starnberg, with additional locations in Weilheim (PARItec, production) and Gräfelfing (PARI Pharma, medicinal products and eFlow technology). In addition, there are international subsidiaries and a worldwide distribution network.
PARI gained its reputation in the first half of the 20th century with a revolutionary invention: nozzles These allowed the atomization of solutions into a respirable aerosol. Initially, applications were only possible in clinics and practices. The next ground-breaking step was an electrically-powered, portable inhalation device, which allowed therapy to be carried out at home. PARI continues to develop nozzle-nebulizer technology: for an effective therapy with quality of life.
Another milestone has been the development of nebuliser devices based on oscillating-membrane technology. This allowed much smaller, almost silent devices with faster aerosol production and higher output. This changed a lot for the patients: independent of the power grid, they can now nebulise quietly anytime and anywhere - a great plus in the quality of life. This benefits all user groups, from people who nebulise preventatively to patients with chronic respiratory diseases requiring frequent treatments.